Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genentech, Inc.
Xeloda®-Oxaliplatin Combination XELOX Shown to Be More Effective Than Standard Chemotherapy Regimen in Adjuvant Colon Cancer
August 3rd, 2009
Genentech, Inc. announced that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery. The data show those who participated in the study and took XELOX immediately after surgery lived longer without their cancer being detectable than those who took intravenous 5U/LV. No new adverse events related to Xeloda were observed in the study. Data from the trial will be submitted for presentation at...
Source: Biotech Business Week (2009-08-03)
|
